Derek Hicks - Jan 3, 2022 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Business Officer
Signature
/s/ James Basta, Attorney-in-fact
Stock symbol
NTLA
Transactions as of
Jan 3, 2022
Transactions value $
$0
Form type
4
Date filed
1/5/2022, 03:15 PM
Previous filing
Dec 29, 2021
Next filing
Jan 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Award $0 +19.1K $0.00 19.1K Jan 3, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock option (right to buy) Award $0 +25K $0.00 25K Jan 3, 2022 Common Stock 25K $118.99 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2 This option was granted on January 3, 2022 with respect to 25,000 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 25% vesting on December 20, 2022 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter.